Merck’s Focus on Cancer

13 May 2021 | Thursday | News


First-Time Data for KEYTRUDA® (pembrolizumab) in Early-Stage Kidney Cancer and for LYNPARZA® (olaparib) in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer
Image Source : Scientific American

Image Source : Scientific American

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program

 

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8. These data include new or updated findings from Merck’s broad oncology portfolio and diverse pipeline including KEYTRUDA, Merck’s anti-PD-1 therapy; LYNPARZA (in collaboration with AstraZeneca); LENVIMA® (lenvatinib, in collaboration with Eisai); and belzutifan, an investigational hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor.

“Our expansive oncology clinical development program is designed to help us understand the full potential of our established and pipeline medicines and identify new avenues of treatment, including in earlier lines of therapy and in combination with other oncology therapies,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “At this year’s ASCO, we will present new clinical and real-world data highlighting how our oncology medicines are making a meaningful impact on the lives of people with cancer and driving forward future innovations in cancer care.”

 

Merck’s Focus on Cancer

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. 

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close